

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-QSB

(Mark One)

- ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities  
Exchange Act of 1934  
For the Quarterly Period Ended September 30, 2001  
or  
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities  
Exchange Act of 1934  
For the Transition Period From \_\_\_\_\_ to \_\_\_\_\_.

Commission file number 000-25727

THE CHROMALINE CORPORATION

-----  
(Exact name of small business issuer as specified in its charter)

Minnesota

41-0730027

-----  
(State or other jurisdiction of  
incorporation or organization)

-----  
(I.R.S. employer  
identification no.)

4832 Grand Avenue  
Duluth, Minnesota

55807

-----  
(Address of principal executive offices)

-----  
(Zip code)

(218) 628-2217

-----  
Issuer's telephone number

Not Applicable

-----  
(Former name, former address and former fiscal year, if changed since last  
report)

Check whether the issuer (1) filed all reports required to be filed by  
Section 13 or 15(d) of the Securities Exchange Act during the preceding 12  
months (or for such shorter period that the registrant was required to file such  
reports), and (2) has been subject to such filing requirements for the past 90  
days.

Yes ☒ No ☐

State the number of shares outstanding of each of the issuer's classes of  
common equity, as of the latest practical date: Common Stock, \$.10 par value -  
1,271,627 shares outstanding as of November 13, 2001.

Transitional Small Business Disclosure Format (check one): Yes ☐ No ☒

THE CHROMALINE CORPORATION

QUARTERLY REPORT ON FORM 10-QSB

<TABLE>  
<CAPTION>

PART I.	FINANCIAL INFORMATION	PAGE NO.
	-----	-----
<S>	<C>	<C>
Item 1.	Financial Statements:	
	Balance Sheets as of September 30, 2001 and December 31, 2000	3
	Statements of Operations for the Three Months and Nine Months Ended September 30, 2001 and 2000	4
	Statements of Cash Flows for the Nine Months Ended September 30, 2001 and 2000	5
	Notes to Financial Statements	6

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	8
PART II.	OTHER INFORMATION	13
	SIGNATURES	15

## PART I -- FINANCIAL INFORMATION

## ITEM 1. FINANCIAL STATEMENTS

THE CHROMALINE CORPORATION  
BALANCE SHEETS<TABLE>  
<CAPTION>

	SEPTEMBER 30 2001	DECEMBER 31 2000
<S>	<C>	<C>
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 457,926	\$ 71,493
Marketable securities	232,358	664,156
Trade receivables, less allowance for doubtful accounts of \$92,400 and \$32,400 respectively	1,569,075	1,639,046
Inventories	1,739,323	1,525,993
Prepaid expenses and other assets	197,312	128,369
Income tax refund receivable	180,305	231,110
Deferred taxes	59,000	59,000
	-----	-----
Total current assets	4,435,299	4,319,167
PROPERTY, PLANT, AND EQUIPMENT, at cost:		
Land and building	1,338,098	1,333,787
Machinery and equipment	2,459,958	2,389,498
Office equipment	719,514	635,590
Vehicles	241,631	241,631
	-----	-----
	4,759,201	4,600,506
Less accumulated depreciation	3,464,842	3,191,974
	-----	-----
	1,294,359	1,408,532
PATENT, net of amortization of \$30,535 and \$23,776 respectively	78,743	85,502
GOODWILL, net of amortization of \$18,207 and \$7,283 respectively	200,290	211,214
NONCOMPETE AGREEMENT, net of amortization of \$8,334 and \$3,334 respectively	91,666	96,666
INVESTMENT IN APPRISE TECHNOLOGIES	187,500	112,500
DEFERRED TAXES	105,000	105,000
	-----	-----
	\$ 6,392,857	\$ 6,338,581
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 393,835	\$ 359,081
Accrued compensation	192,125	167,075
Other accrued expenses	23,087	26,488
	-----	-----
Total current liabilities	609,047	552,644
STOCKHOLDERS' EQUITY:		
Preferred stock, par value \$.10 per share; authorized 250,000 shares; issued none		
Common stock, par value \$.10 per share; authorized 4,750,000 shares; issued and outstanding 1,271,627 shares	127,163	127,163
Additional paid-in capital	1,293,460	1,293,460
Retained earnings	4,361,296	4,376,147
Accumulated other comprehensive income (loss)	1,891	(10,833)
	-----	-----

Total stockholders' equity

5,783,810	5,785,937
-----	-----
\$ 6,392,857	\$ 6,338,581
=====	=====

</TABLE>

See notes to financial statements.

3

THE CHROMALINE CORPORATION  
STATEMENTS OF OPERATIONS

<TABLE>  
<CAPTION>

	THREE MONTHS ENDED SEPTEMBER 30		NINE MONTHS ENDED SEPTEMBER 30	
	2001	2000	2001	2000
<S>	<C>	<C>	<C>	<C>
SALES	\$2,519,461	\$ 2,500,781	\$ 8,068,707	\$ 7,776,547
COSTS AND EXPENSES:				
Cost of goods sold	1,505,750	1,302,751	4,557,270	3,960,424
Selling, general, and administrative	938,540	988,858	2,975,168	2,781,334
Research and development	198,278	197,728	599,221	585,191
--	-----	-----	-----	-----
7,326,949	2,642,568	2,489,337	8,131,659	
--	-----	-----	-----	-----
INCOME (LOSS) FROM OPERATIONS	(123,107)	11,444	(62,952)	449,598
INTEREST INCOME	11,344	24,287	39,001	
67,518	-----	-----	-----	-----
--				
INCOME (LOSS) BEFORE INCOME TAXES	(111,763)	35,731	(23,951)	517,116
FEDERAL AND STATE INCOME TAX EXPENSE (BENEFIT)	(37,700)	14,000	(9,100)	197,000
--	-----	-----	-----	-----
NET INCOME (LOSS)	\$ (74,063)	\$ 21,731	\$ (14,851)	\$ 320,116
	=====	=====	=====	=====
EARNINGS (LOSS) PER SHARE:				
Basic	\$ (0.06)	\$ 0.02	\$ (0.01)	\$
0.25	=====	=====	=====	=====
Diluted	\$ (0.06)	\$ 0.02	\$ (0.01)	\$
0.25	=====	=====	=====	=====
WEIGHTED AVERAGE COMMON SHARES ASSUMED OUTSTANDING:				
Basic	1,271,627	1,296,922	1,271,627	1,297,678
	=====	=====	=====	=====
Diluted	1,271,627	1,301,961	1,271,627	1,303,941
	=====	=====	=====	=====

</TABLE>

See notes to financial statements.

4

THE CHROMALINE CORPORATION  
STATEMENTS OF CASH FLOWS

<TABLE>  
<CAPTION>

	NINE MONTHS ENDED SEPTEMBER 30	
	2001	2000
<S>	<C>	<C>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income (loss)	\$ (14,851)	\$ 320,116
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	295,552	300,357
Non-cash charge for Chromaline Europe S.A. investment write-off		53,997
Changes in working capital components:		
Decrease (increase) in:		
Trade receivables	69,971	231,113
Prepaid expenses and other assets	(68,943)	(207,238)
Inventories	(213,330)	(214,558)
(Decrease) increase in:		
Accounts payable	34,754	(53,051)
Accrued expenses	21,649	(2,857)
Accrued legal costs		(27,813)
Income taxes payable/receivable	50,805	(54,838)
	-----	-----
Net cash provided by operating activities	175,607	345,228
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of property and equipment	(158,695)	(156,223)
Activity in marketable securities	444,521	(37,726)
Purchase of assets net of liabilities assumed		(444,532)
Note receivable	(75,000)	
Investment		(127,765)
	-----	-----
Net cash provided by (used in) investing activities	210,826	(766,246)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repurchase of common stock		(9,609)
	-----	-----
Net cash provided by (used in) financing activities		(9,609)
	-----	-----
NET INCREASE(DECREASE) IN CASH AND CASH EQUIVALENTS	386,433	(430,627)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	71,493	706,345
	-----	-----
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 457,926	\$ 275,718
	=====	=====
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Income taxes paid (refunded)	\$ (59,905)	\$ 269,000
	=====	=====
NON-CASH:		
Loan receivable converted to stock of invested company	\$ 75,000	\$ 0
	=====	=====

</TABLE>

See notes to financial statements.

THE CHROMALINE CORPORATION  
NOTES TO FINANCIAL STATEMENTS

1. Notes to Financial Statements

The balance sheet of The Chromaline Corporation (the Company) as of September 30, 2001, and the related statements of operations for the three and nine months ended September 30, 2001 and 2000, and cash flows for the nine months ended September 30, 2001 and 2000, have been prepared without being audited.

In the opinion of management, these statements reflect all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position of The Chromaline Corporation as of September 30, 2001, and the results of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial statements, prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. Therefore, these statements should be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2000 Form 10-KSB.

The results of operations for interim periods are not necessarily indicative of results that will be realized for the full fiscal year.

2. Inventory

The major components of inventory at September 30, 2001 and December 31, 2000 are as follows:

<TABLE>  
<CAPTION>

	Sept 30, 2001	Dec 31, 2000
	-----	-----
<S>	<C>	<C>
Raw materials	\$ 688,236	\$ 550,340
Work-in-progress	342,422	326,266
Finished goods	925,785	839,507
Reduction to LIFO cost	(217,120)	(190,120)
	-----	-----
Total Inventory	\$1,739,323	\$1,525,993
	=====	=====

</TABLE>

3. Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 141, "Business Combinations" and No. 142 "Goodwill and Other Intangible Assets". SFAS No. 141 requires that the purchase method of accounting be used for all business combinations initiated after June 30, 2001 and that the use of the pooling-of-interest method is no longer allowed. SFAS No. 142 requires that upon adoption, amortization of goodwill will cease and instead, the carrying value of goodwill will be evaluated for impairment on an annual basis. Identifiable intangible assets will continue to be amortized over their useful lives and reviewed for impairment in accordance with SFAS No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of". SFAS No. 142 is effective for the Company's fiscal year beginning January 1, 2002. The

Company is evaluating the impact of the adoption of these standards and has not yet determined the effect of adoption on its financial position and results of operations.

4. Stockholders' Equity

<TABLE>  
<CAPTION>

		Nine Months Ended September 30, 2001 -----
<S>	<C>	<C>
Total Stockholders' Equity-December 31, 2000		\$ 5,785,937
Net loss	\$ (14,851)	
Unrealized gain on available- for-sale investments	12,724	
	-----	
Comprehensive loss		(2,127)
		-----
Total Stockholders' Equity-September 30, 2001		\$ 5,783,810
		=====

</TABLE>

5. Net Income per Common Share

Basic and diluted earnings per share are presented in accordance with Statement of Financial Accounting Standards (SFAS) No. 128, "Earnings per Share". The difference between average common shares and average common and common equivalent shares is the result of outstanding stock options.

6. Reclassifications

Certain reclassifications were made to the September 30, 2000 financial statements to conform to the September 30, 2001 presentation. Certain shipping and handling costs that had previously been netted in sales are now presented as cost of goods sold to conform to the Emerging Issues Task Force number 00-10 Accounting for Shipping and Handling Fees and Costs. This resulted in a \$127,321 increase to sales and a \$364,738 increase to cost of goods sold in the statement of operations for the three and nine months ended September 30, 2000, respectively. These reclassifications had no impact on net income or stockholders' equity as previously reported.

THE CHROMALINE CORPORATION

The information presented below in Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties, including those discussed under "Factors that May Affect Future Results" below, that could cause actual results to differ materially from projected results. Because actual results may differ, readers are cautioned not to place undue reliance on these forward-looking statements. Certain forward-looking statements below are indicated by italics.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following management's discussion and analysis focuses on those factors that had a material effect on the Company's financial results of operations during the third quarter of 2001 and nine months ended September 30, 2001 and during the same periods of 2000. It should be read in connection with the Company's unaudited financial statements and notes thereto included in this Form 10-QSB.

FACTORS THAT MAY AFFECT FUTURE RESULTS

Certain statements made in this Quarterly Report on Form 10-QSB, which are summarized below, are forward-looking statements that involve risks and uncertainties, and actual results may be materially different. Factors that could cause actual results to differ include, but are not limited to, those identified as follows:

- The Company's plans to continue to invest in research and development efforts and the expected focus and results of such efforts--These plans and expectations may be impacted by general market conditions, unanticipated changes in expenses or sales, delays in the development of new products, technological advances or other changes in competitive conditions.
- The belief that the Company's current financial resources, its line of credit, cash generated from operations and the Company's capacity for debt and/or equity financing will be sufficient to fund current and anticipated business operations--Changes in anticipated

operating results, credit availability and equity market conditions may further enhance or inhibit the Company's ability to maintain or raise appropriate levels of cash.

- The Company's belief that its vulnerability to foreign currency fluctuations and general economic conditions in foreign countries is not significant--This belief may be impacted by economic, political and social conditions in foreign markets and changes in regulatory and competitive conditions or a change in the amount or geographic focus of the Company's international sales.
- The Company's efforts to grow its international business--These efforts may be impacted by economic, political and social conditions in current and anticipated foreign markets, regulatory conditions in such markets, unanticipated changes in expenses or sales, changes in competitive conditions or other barriers to entry or expansion.
- The Company's plan to seek acquisitions--This plan may be impacted by general market conditions, competitive conditions in the Company's industry, unanticipated changes in the Company's financial position or the inability to identify attractive acquisition targets.
- The Company's plans to vigorously market its ImagePro Super products and defend its legal rights - This plan may be impacted by general market conditions, changes in competitive conditions in the Company's industry and difficulties faced by the Company in enforcing its legal rights.
- The Company's belief that the next generation of its U.V. Minder product will have a broader range of applications--This belief may be impacted by the success of the Company's development efforts and by regulatory or competitive changes in the market for this product.

## RESULTS OF OPERATIONS

### QUARTER ENDED SEPTEMBER 30, 2001 COMPARED TO QUARTER ENDED SEPTEMBER 30, 2000

**Sales.** The Company's sales during the third quarter of 2001 increased to \$2.52 million, or 0.8%, from the \$2.50 million in sales during the same period in 2000. Prior year third quarter sales were adjusted upward \$127,000 for the third quarter of 2000, as the Company recorded an income statement reclassification to conform to Emerging Issues Task Force (EITF) issue No. 00-10, Accounting for Shipping and Handling Fees and Costs, which the Company was required to adopt at the end of fiscal 2000. This EITF requires shipping costs to be accounted for consistently by all companies. Cost of goods sold were adjusted upward by the same amount. Sales to the screen printing industry in the United States decreased \$207,000, or 18.0% as compared to the third quarter of 2000, reflecting a continuing weak market, especially among electronics manufacturers. International screen printing sales increased \$33,000, or 5.0%, in the third quarter of 2001 over the same period in 2000, due mainly to growing sales in Europe. This Company believes this is significant considering that Chromaline Europe S.A. was liquidated in September 2000 and the Company began direct selling in Europe shortly after this liquidation. Sales of the Company's PhotoBrasive products increased \$143,000, or 25%, over the third quarter of 2000. This continued to be the result of the full re-introduction of film products covered by the Aicello lawsuit that was settled in January 2001. Also contributing were sales of crystal glass being sold by the Company with its distribution arrangement with The Slee Corporation of Chicago, Illinois.

**Cost of Goods Sold.** Cost of goods sold during the third quarter of 2001 was \$1.51 million, or 59.8% of sales, compared to \$1.30 million, or 52.0% of sales, during the same period in 2000. The increase in the third quarter of 2001 was due to a shift in the Company's product mix within its domestic U.S. decorative sandblasting market. Specifically, there was an increase in crystal glass sales that have lower margins and there were equipment promotions to spur film sales.

**Selling, General and Administrative Expenses.** Selling, general and administrative expenses decreased to \$939,000, or 37.3% of sales, in the third quarter of 2001, from \$989,000, or 39.6% of sales, for the same period in 2000. The third quarter of 2001 includes a \$15,000 increase in the Company's bad debt allowance reflecting the risk associated with an increased presence in Europe and India. The Company also added a Marketing Director in the fourth quarter of 2000, and is experiencing increased sales and marketing costs related to trade shows and advertising. These increased costs were less than the \$149,000 write-off in the third quarter of 2000 related to the liquidation of Chromaline Europe S.A.

**Research and Development Expenses.** Research and development expenses

during the third quarter of 2001 were \$198,000, or 7.9% of sales, equaling the \$198,000, or 7.9% of sales, for the same period in 2000. There were no significant differences in research and development spending during the two quarters of operation for purposes of this discussion.

Interest Income. Interest income decreased to \$11,000 for the third quarter of 2001 from \$24,000 for the same period in 2000. The decrease was due to the utilization of invested cash resources for an additional investment in Apprise Technologies of Duluth, Minnesota. It also included investments in inventory for the Nichols chemical product line, ultraviolet light measuring devices being manufactured by Apprise and sold by Chromaline, and inventory for a dry film product used for photopositive development from a laser printer being sold by the Company under the name AccuArt according to the terms of a distribution agreement with Mile High Engineering of Denver, Colorado.

Income Taxes. An income tax benefit was recorded of \$38,000, for an effective rate of 34%, for the third quarter of 2001, compared to an income tax expense of \$14,000, or an effective rate of 39%, in the third quarter of 2000. In some instances, there may be a difference in the effective rate due to permanent differences for allowable tax deductions including foreign sales corporation credits.

NINE MONTHS ENDED SEPTEMBER 30, 2001 COMPARED TO THE NINE MONTHS ENDED SEPTEMBER 30, 2000

Sales. The Company's sales during the first nine months of 2001 increased to \$8.07 million, or 3.8%, from the \$7.78 million in sales during the same period in 2000. Prior year sales were adjusted upward \$365,000 as the Company recorded an income statement reclassification to conform to EITF issue No. 00-10, Accounting for Shipping and Handling Fees and Costs, which the Company was required to adopt at the end of fiscal 2000. This EITF requires shipping costs to be accounted for consistently by all companies. Cost of goods sold were adjusted upward by the same amount. Sales to the domestic U.S. screen printing market were down \$232,000, or 7.0%, from the same period in 2000. The weakening U.S. economy has hurt domestic sales as the year has progressed, especially in the electronics industry. International sales during the first nine months of 2001 increased \$47,000, or 2.0%. Sales in Europe have been strong since the Company began direct selling after Chromaline Europe S.A. was liquidated in September 2000. Sales of the Company's PhotoBrasive products increased \$276,000, or 15.0%, over the same period in 2000, due primarily to crystal glass sales being marketed with The Slee Corporation of Chicago, Illinois. During the first nine months of 2001, film product sales have increased as a result of the Company's re-introduction of these products based on the settlement of the lawsuit with the Aicello Corporation in January 2001.

Cost of Goods Sold. Cost of goods sold during the first nine months of 2001 was \$4.56 million, or 56.5% of sales, compared to \$3.96 million, or 50.9% of sales, during the same period in 2000. The increase during this period was due to a shift in the Company's product mix within its domestic U.S. decorative sandblasting market. Specifically, there was an increase in crystal glass sales that have lower margins and there were equipment promotions to spur film sales.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased to \$2.98 million, or 36.9% of sales, for the first nine months of 2001, from \$2.78 million, or 35.7% of sales, for the same period in 2000. The first nine months of 2001 includes a \$60,000 increase in the Company's bad debt allowance reflecting the risk associated with an increased presence in Europe and India. It also includes legal fees of \$104,000 related to the settlement of the Aicello lawsuit and the ancillary costs to terminate the case. As part of this settlement, the Company incurred royalty costs to Aicello of \$75,000. The Company also added a Marketing Director in the fourth quarter of 2000. The balance of the change was due to increased sales and marketing costs related to trade shows and advertising, partially offset by severance costs of \$85,000 associated with the resignation of its CEO on February 7, 2000 and a \$149,000 write-off in September 2000 for the liquidation of Chromaline Europe S.A.

Research and Development Expenses. Research and development expenses during the first nine months of 2001 were \$599,000, or 7.4% of sales, versus \$585,000, or 7.5% of sales, for the same period in 2000. The Company incurred incremental costs of \$57,000 in 2001 for the operation of its lab in Lakeville, Minnesota, purchased as part of the Nichols acquisition. These higher costs were offset by lower expenses for production trials and travel.

Interest Income. Interest income decreased to \$39,000 for the first nine months of 2001 compared to \$68,000 for the same period in 2000. The decrease was due to the utilization of invested cash resources for an additional \$75,000 investment in Apprise Technologies of Duluth, Minnesota. The Company also made a prepaid royalty payment to Aicello Corporation of \$150,000 in February 2001. It also includes investments in inventory for the Nichols



chemical product line, ultraviolet light measuring devices being manufactured by Apprise and sold by Chromaline, and inventory for a dry film product used for photopositive development from a laser printer being sold by the Company under terms of a distribution agreement with Mile High Engineering of Denver, Colorado.

Income Taxes. An income tax benefit of \$9,000 was recorded for the nine months ended September 30, 2001, for an effective rate of 38%, compared to an income tax expense of \$197,000, or an effective rate of 38%, for the same period in 2000. The difference in the effective rate is due to permanent differences for allowable tax deductions including foreign sales corporation credits.

#### LIQUIDITY AND CAPITAL RESOURCES

The Company has financed its operations principally with funds generated from operations. These funds have been sufficient to cover the Company's normal operating expenditures and annual capital requirements, research and development expenditures, the Nichols acquisition in June 2000 and an investment in Apprise Technologies of Duluth, Minnesota in 2001.

Cash and cash equivalents were \$458,000 and \$276,000 at September 30, 2001 and September 30, 2000, respectively. The Company generated \$176,000 in cash from operating activities during the nine months ended September 30, 2001, and generated \$345,000 for the same period in 2000. Cash generated by operating activities is primarily provided by net income (loss) as adjusted for non-cash depreciation. During the first nine months of 2001, trade receivables decreased by \$70,000 reflecting limited sales growth and an increased effort to reduce days sales outstanding (DSO). Prepaid expenses increased \$69,000 reflecting a \$150,000 prepaid royalty to Aicello in February 2001. Inventories increased \$213,000 due to an increase in raw materials and finished goods for several new product launches. Accounts payable increased \$35,000 and accrued expenses increased \$22,000.

For the nine months ended September 30, 2000, trade receivables decreased \$231,000 due to increased collections and the write-off of the receivable from the liquidated Chromaline Europe, S.A. organization. Prepaid expenses increased \$207,000 reflecting certain marketing expenses. Inventories increased \$215,000 due to raw materials and the new Nichols chemical line purchased in June 2000. Accounts payable decreased \$53,000 reflecting the timing of payments. Accrued expenses decreased \$3,000 during the first nine months of 2000. Accrued legal costs decreased \$28,000 during the same period of 2000. Income tax payable decreased \$55,000 reflecting quarterly federal and state tax deposits. Income tax receivable decreased \$51,000 over the first nine months of 2001 reflecting an over deposit of federal and state taxes in 2000.

The Company generated \$211,000 and used \$766,000 in cash for investing activities during the nine months ended September 30, 2001 and September 30, 2000, respectively. The Company participated in a bridge loan to Apprise Technologies of Duluth, Minnesota for \$75,000 in February 2001. This loan was converted to stock and warrants in Apprise on April 30, 2001. The Company previously purchased stock and warrants in Apprise for \$112,500 in August 2000, bringing the total investment in Apprise to \$187,500. During the first half of 2001, the Company sold a certain number of its investment holdings in general revenue obligation bonds. These proceeds were used to participate in the Apprise bridge loan. These proceeds also funded the \$150,000 prepaid royalty to Aicello as part of the license agreement entered into pursuant to the lawsuit settlement and funded the \$73,000 prepaid production costs to Apprise for the radiometer project. The funds used during the first nine months of 2000 were primarily for the acquisition of Nichols in June 2000. During the nine months ended September 30, 2001 and September 30, 2000, net cash used for investing activities for plant and equipment was \$159,000 and \$156,000, respectively.

The Company generated no additional cash financing activities during the first nine months of 2001. During the same period in 2000, the Company purchased 1,729 shares of its common stock on the open market.

A bank line of credit exists providing for borrowings of up to \$1,250,000. Outstanding debt under this line of credit is collateralized by accounts receivable and inventory and bears interest at 2.25 percentage points over the 30-day LIBOR rate. The Company has not utilized this line of credit and there is no debt outstanding under this line as of September 30, 2001.

The Company believes that current financial resources, its line of credit, cash generated from operations and the Company's capacity for debt and/or equity financing will be sufficient to fund current and anticipated business operations. Future activities undertaken to expand the Company's business may include acquisitions, building expansion and additions, equipment additions, new product development and marketing opportunities.

## CAPITAL EXPENDITURES

Through September 30, 2001, the Company had spent \$158,695 on capital expenditures in 2001. This spending included plant equipment, marketing-related equipment and business software.

11

Commitments for capital expenditures of \$50,000 include ongoing manufacturing equipment upgrades, development equipment to modernize the capabilities and processes of Chromaline's laboratory and research and development to improve measurement and quality control processes. The Company is progressing with its plans to replace its business software in 2001 in order to improve internal reporting for decision-making purposes and improve the efficiency of administrative and manufacturing operations. The cost of this project is estimated to be \$140,000, with \$81,000 expended during the third quarter. The remaining commitments are expected to be funded with cash generated from operating activities.

## ACCOUNTING PRONOUNCEMENT

In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 141, "Business Combinations" and No. 142 "Goodwill and Other Intangible Assets". SFAS No. 141 requires that the purchase method of accounting be used for all business combinations initiated after June 30, 2001 and that the use of the pooling-of-interest method is no longer allowed. SFAS No. 142 requires that upon adoption, amortization of goodwill will cease and instead, the carrying value of goodwill will be evaluated for impairment on an annual basis. Identifiable intangible assets will continue to be amortized over their useful lives and reviewed for impairment in accordance with SFAS No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of". SFAS No. 142 is effective for the Company's fiscal year beginning January 1, 2002. The Company is evaluating the impact of the adoption of these standards and has not yet determined the effect of adoption on its financial position and results of operations.

## INTERNATIONAL ACTIVITY

The Company markets its products to over 50 countries in North America, Europe, Latin America, Asia and other parts of the world. Foreign sales were approximately 30% of total sales for the three months ended September 30, 2001. This compares with foreign sales accounting for 28% of total sales during the same period in 2000. Sales to foreign markets for the nine months ended September 30, 2001 were 32% of total sales compared to 31% for the same period in 2000. Foreign sales in the third quarter of 2001 were higher as a percentage of total sales from the second quarter of 2001 due to continued strong sales in Europe combined with lower sales to the domestic United States markets. Foreign sales in 2000 were impacted by the strong U.S. dollar resulting in lower selling prices. The weakening of certain foreign currencies has not significantly impacted the Company's operations because the Company's foreign sales are not concentrated in any one region of the world. The Company believes its vulnerability to uncertainties due to foreign currency fluctuations and general economic conditions in foreign countries is not significant.

Substantially all of the Company's foreign transactions are negotiated, invoiced and paid in U.S. dollars. A portion of the Company's foreign sales are invoiced and paid in Eurodollars. Chromaline has not implemented a hedging strategy to reduce the risk of foreign currency translation exposures, which management does not believe to be significant based on the scope and geographic diversity of the Company's foreign operations as of September 30, 2001.

## FUTURE OUTLOOK

Chromaline has invested over 6% of its sales dollars for the past several years in research and development. The Company plans to continue its efforts in this area and expedite internal product development as well as form technological alliances with outside experts to ensure commercialization of new product opportunities. In addition to its film, emulsion and self-adhesive products, Chromaline's research and development efforts will also focus on improving the efficiency of its automated photo developers for the decorative sand blasting product line.

In addition to its traditional emphasis on domestic markets, the Company will continue efforts to grow its business internationally by attempting to develop new markets and expanding market share where it has already established a presence.

In January 2001, the Company formed a marketing alliance with The Slee Corporation of Chicago, Illinois. Under the terms of the agreement, the Company's PhotoBrasive Systems division becomes a "Master Distributor" of Slee's Crystal Edge Recognition series of glass and crystal products. Slee is an industry leader in crystal recognition products world-wide and will continue to market and sell its products through its organization. This arrangement enhances the Company's product offerings as a one-stop purchasing option for its customers.

During 1999, the Company began evaluating potential acquisitions. In June 2000, the Company purchased the assets and assumed certain liabilities of Nichols. Nichols produces an environmentally friendly line of screen preparation and cleaning products that fully complements the products offered by Chromaline. This new line of products broadens the market offerings to the screen printing industry. The Company plans to continue to look for opportunities that complement its existing business and technologies. The search and evaluation process continues to proceed in a cautious and prudent manner. The Company's goal is to capitalize on its strong cash and low debt positions as well as the strengths of the Company's core businesses in order to grow shareholder value.

In January 2001, the Company announced it had signed a co-exclusive licensing agreement with Aicello Chemical Co. Ltd. of Japan and Aicello North America, Inc. ending the patent litigation between the parties. Under the terms of the agreement, Aicello North America and Chromaline's PhotoBrasive division are the sole legal North American distributors of the photo resist technology patented by the Aicello Chemical Co. Aicello will receive certain royalties under the agreement, terminate its lawsuit against Chromaline and may distribute certain Chromaline products. This action represented an end to the legal expenses incurred by the Company related to the suit of approximately \$600,000 over the past four years. The Company has now re-introduced its ImagePro Super products that were previously withdrawn from the market. The Company plans to vigorously market these products and defend its North American legal rights to practice the core technology of the photo resist market.

During the first nine months of 2001, the Company has collaborated with Apprise Technologies of Duluth,, Minnesota to develop an ultraviolet light measuring device being sold under the name of U.V. Minder. This product is being marketed to printers and other technology companies requiring strict and repeatable light tolerances for consistent product output. The next generation of this product is currently being developed which the Company believes will have a broader range of applications.

During the first half of 2001, the Company began selling a dry film in conjunction with Mile High Engineering of Denver, Colorado. This film is being marketed under the name of AccuArt. This film is used to produce photopositives directly form a laser printer resulting in a quality product that is much less time intensive and at a much reduced cost to produce. The Company believes that market acceptance of this product is growing.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

None

### ITEM 2. CHANGES IN SECURITIES

None

### ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable

### ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable

### ITEM 5. OTHER INFORMATION

None

### ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

#### (A) EXHIBITS

The following exhibits are filed as part of this Quarterly Report on Form 10-QSB for the quarterly period ended September 30, 2001:

<TABLE>  
<CAPTION>

Exhibit	Description
- - - - -	- - - - -
<S>	<C>
3.1	Restated Articles of Incorporation of Company, as amended.(1)
3.2	By-Laws of the Company, as amended.(1)
11	Computation of Net Earnings per Common Share

</TABLE>

Copies of Exhibits will be furnished upon request and payment of the Company's reasonable expenses in furnishing the Exhibits.

(B) REPORTS ON FORM 8-K

No reports on Form 8-K were filed by the registrant during the quarterly period ended September 30, 2001.

- - - - -  
(1) Incorporated by reference to the like numbered Exhibit to the Company's Registration Statement on Form 10-SB (File No. 000-25727).

14

#### THE CHROMALINE CORPORATION

#### SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

<TABLE>  
<S><C>

THE CHROMALINE CORPORATION

DATE: November 13, 2001

By: /s/ Jeffery A. Laabs

-----  
Jeffery A. Laabs,  
Chief Financial Officer, Treasurer and Secretary  
(Duly authorized officer and  
Principal Financial Officer)

</TABLE>

15  
INDEX TO EXHIBITS

<TABLE>  
<CAPTION>

Exhibit	Description	Page
- - - - -	- - - - -	- - - -
<S>	<C>	<C>
3.1	Restated Articles of Incorporation of Company, as amended.....	Incorporated by Reference
3.2	By-Laws of the Company, as amended.....	Incorporated by Reference
11	Computation of Net Earnings per Common Share.....	Filed Electronically
</TABLE>		

Exhibit 11

THE CHROMALINE CORPORATION  
COMPUTATION OF NET EARNINGS PER COMMON SHARE  
(Unaudited)

<TABLE>  
<CAPTION>

	Nine Months Ended	
	September 30, 2001	September 30, 2000
	-----	-----
<S>	<C>	<C>
Net earnings (loss) applicable to common shareholders for basic and diluted earnings per share	\$ (14,851)	\$ 320,116
Weighted average shares outstanding for basic earnings per share	1,271,627	1,297,678
Dilutive effect of stock options computed using the treasury stock method and the average market price	0	6,263
Weighted average shares outstanding for diluted earnings per share	1,271,627	1,303,941
Basic earnings (loss) per share	\$ (0.06)	\$ 0.25
Diluted earnings (loss) per share	\$ (0.06)	\$ 0.25

</TABLE>